PMID- 19262718
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20240316
IS  - 1934-7820 (Print)
IS  - 1934-7987 (Electronic)
IS  - 1934-7820 (Linking)
VI  - 1
IP  - 2
DP  - 2007 Mar
TI  - Capecitabine and timing of radiotherapy during preoperative chemoradiation for 
      rectal cancer.
PG  - 44-8
AB  - BACKGROUND: Capecitabine is effective in treating colorectal cancer and is 
      increasingly being investigated for use in preoperative chemoradiation of rectal 
      cancer. Since capecitabine and its metabolites have a plasma half-life of 0.5-1 
      hour, the relative timing of capecitabine and radiotherapy may affect clinical 
      outcomes. We retrospectively investigated whether the timing of radiotherapy 
      affects rates of acute toxicity, pathologic response, and relapse in rectal 
      cancer patients receiving capecitabine. METHODS: Between June 2001 and July 2004, 
      111 rectal cancer patients were treated with preoperative radiotherapy and 
      concurrent capecitabine given twice daily, in the early morning and at night. Of 
      these, 44 received at least 70% of their radiation treatments before 12 PM (AM 
      group), and 47 received at least 70% of their radiation treatments after 12 PM 
      (PM group). RESULTS: There were no significant differences between the AM vs. PM 
      groups in rates of grade >/= 2 acute gastrointestinal toxicity (61% vs. 47%) or 
      skin toxicity (23% vs. 26%) or grades >/= 1 hand-foot syndrome (27% vs. 15%). 
      Although the PM group had numerically higher rates of pathologic complete 
      response (28% vs. 16%) and tumor downstaging (57% vs. 39%), differences in these 
      outcomes and in sphincter preservation were not significant. Rates of 2-year 
      local control, distant control, and disease-free survival were nearly identical 
      in the two groups. CONCLUSIONS: No significant differences were seen in the rates 
      of acute toxicity, pathologic response, and relapse between patients in the AM 
      and PM groups. The timing of radiotherapy does not appear to be critical in 
      patients with rectal cancer receiving concurrent capecitabine.
FAU - Bedi, Manpreet
AU  - Bedi M
AD  - Department of Radiation Oncology, The University of Texas M. D. Anderson Cancer 
      Center, Houston, TX.
FAU - Das, Prajnan
AU  - Das P
FAU - Skibber, John M
AU  - Skibber JM
FAU - Rodriguez-Bigas, Miguel A
AU  - Rodriguez-Bigas MA
FAU - Chang, George J
AU  - Chang GJ
FAU - Eng, Cathy
AU  - Eng C
FAU - Wolff, Robert A
AU  - Wolff RA
FAU - Janjan, Nora A
AU  - Janjan NA
FAU - Krishnan, Sunil
AU  - Krishnan S
FAU - Crane, Christopher H
AU  - Crane CH
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Gastrointest Cancer Res
JT  - Gastrointestinal cancer research : GCR
JID - 101300691
PMC - PMC2632878
EDAT- 2007/03/01 00:00
MHDA- 2007/03/01 00:01
PMCR- 2007/03/01
CRDT- 2009/03/06 09:00
PHST- 2009/03/06 09:00 [entrez]
PHST- 2007/03/01 00:00 [pubmed]
PHST- 2007/03/01 00:01 [medline]
PHST- 2007/03/01 00:00 [pmc-release]
AID - gcr1_2p0044 [pii]
PST - ppublish
SO  - Gastrointest Cancer Res. 2007 Mar;1(2):44-8.